China CanSinoBIO’s vaccine 57.5 per cent effective against COVID in phase-III trial: Study Reuters Dec 24, 2021 The single-shot Ad5-nCoV vaccine, which CanSinoBIO co-developed with the Chinese military-backed Beijing Institute of…
First COVID-19 vaccine human trial finds it is safe, induces immune response Press Trust of India May 24, 2020 According to the study of 108 adults, the vaccine produced neutralising antibodies, and a response mediated by the immune system's…
